@FierceBiotech: Incyte, Agenus partner on immuno-oncology targets in $410M deal. More | Follow @FierceBiotech
@JohnCFierce: Hey, UK readers. I'm moderating a panel Feb 4 at the Queen Mary Innovation Centre on #biotech finance. Invite only. More | Follow @JohnCFierce
@DamianFierce: Biogen signs a $30M deal with Columbia U. to sequence the genomes of "unusual" patients. Release | Follow @DamianFierce
> Chinese CRO WuXi PharmaTech ($WX) bought NextCODE Health for $65 million in cash, bolstering its genomics heft by integrating the deCODE spinout. News
> Alnylam Pharmaceuticals ($ALNY) and Isis Pharmaceuticals ($ISIS) have extended the RNA-focused partnership, cross-licensing their intellectual property to develop new targeted therapeutics. More
> Regeneron ($REGN) and Sanofi ($SNY) say alirocumab, their in-development cardio drug, performed well as a once-a-month therapy for high cholesterol. Item
Medical Device News
@FierceMedDev: PureTech bumps its early life science funds up to $107M. Story | Follow @FierceMedDev
@EmilyWFierce: Adaptive Biotechnologies snatches up Sequenta to gain ground in cancer immunosequencing Story | Follow @EmilyWFierce
> In a win for Spectranetics, Covidien's to-be-divested drug-coated balloon earns CE mark. News
> C.R. Bard pushes for delay of vaginal mesh trial after judge's call for settlement. Article
Pharma News
@FiercePharma: Catterton offloads PetVet hospital network to Canadian pension plan for $440M. FierceAnimalHealth story | Follow @FiercePharma
@CarlyHFierce: ICYMI yesterday: Court to give speedy answer in Actavis bid to yank old Namenda off market. Report | Follow @CarlyHFierce
> Generics could sink AbbVie below analysts' 2015 estimates. Report
> FDA draws line in sand over its orphan drug policies. Article